Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoladex 10.8 mg q12w vs 3.6 mg q4w in premenopausal ER-positive advanced breast cancer
jRCT2080221070Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by AstraZeneca.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221070.